[{"orgOrder":0,"company":"Re-Vana Therapeutics","sponsor":"Visionary Ventures","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Re-Vana Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Implant","sponsorNew":"Re-Vana Therapeutics \/ Visionary Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Re-Vana Therapeutics \/ Visionary Ventures"},{"orgOrder":0,"company":"Ikarovec","sponsor":"Rentschler Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ikarovec \/ Rentschler Biopharma","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/ Rentschler Biopharma"},{"orgOrder":0,"company":"Ikarovec","sponsor":"UKi2S","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Ikarovec","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ikarovec \/ UKi2S","highestDevelopmentStatusID":"1","companyTruncated":"Ikarovec \/ UKi2S"},{"orgOrder":0,"company":"LGC Group GB","sponsor":"OliX Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"OLX301D","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"LGC Group GB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LGC Group GB \/ OliX Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"LGC Group GB \/ OliX Pharmaceutical"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Under the agreement, Rentschler Biopharma’s ATMP site will support the bioprocess development of AAV material for planned pre-clinical testing of Ikarovec’s novel AAV-based therapy for the treatment of geographic atrophy.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          January 06, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Rentschler Biopharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The proceeds will advance the development of Re-Vana’s novel and proprietary photo-crosslinked EyeLief®, EyeLief-SD™ and OcuLief® biodegradable drug delivery technologies and will enable expansion of the company’s operations and development teams...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 12, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : Visionary Ventures

                          Deal Size : $11.9 million

                          Deal Type : Series A Financing

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Under the terms of the agreement, LGC will produce the active pharmaceutical ingredients for the preclinical and clinical study of OLX301D program, for the treatment of sub-retinal fibrosis and wet macular degeneration.

                          Product Name : OLX301D

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          June 16, 2020

                          Lead Product(s) : OLX301D

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : OliX Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The cash will primarily take the company’s lead programme, a multicistronic gene therapy for diabetic macular edema (DME), to IND-enabling studies.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          May 02, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Undisclosed

                          Sponsor : UKi2S

                          Deal Size : $3.2 million

                          Deal Type : Funding

                          blank